• Belmore Banner Image

    Persuasive Advocacy.
    Proven Results.

    We are experts in intellectual property litigation. We are trial lawyers.
    We are appellate lawyers. We know patent law, inside and out.

    Learn More

News

Read More News

Our Team

Our cases

  • Pharmascience Inc. v Janssen Inc.

    Counsel: Marian Wolanski
    The Supreme Court of Canada released its decision in Pharmascience Inc. v Janssen Inc., 2026 SCC 26 on July 17, 2026, dismissing Pharmascience’s appeal and upholding the validity of our client Janssen’s Invega Sustenna dosing regimen patent.
    Read more

  • Alexion Pharmaceuticals v Amgen Canada

    Counsel: Marian Wolanski
    Belmore Neidrauer along with co-counsel was presented with the LMG Impact Case of the Year – Canada award for our work on Alexion v Amgen (2025 FC 754).
    Read more

  • Samsung Bioepis Co. Ltd. v Janssen Biotech, Inc.

    Counsel: Marian Wolanski
    We represented Janssen. This case related to Janssen’s patent covering its blockbuster drug STELARA. The notice of discontinuance was filed October 2, 2025
    Read more

  • Janssen Inc. v Apotex

    Counsel: Marian Wolanski
    We represented Janssen. This action related to Mitsubishi’s 357 patent covering the diabetes drug INVOKANA. This action was discontinued July 2025.
    Read more

  • Pharmascience v. Janssen

    Counsel: Marian Wolanski
    We represented Janssen. This was an action for damages under section 8 of the Patented Medicines Notice of Compliance Regulations relating to abiraterone acetate. The action was discontinued shortly before trial (May 2025).
    Read more

  • Janssen Inc. v JAMP

    Counsel: Marian Wolanski
    We represented Janssen. This action related to Janssen’s 024 Patent covering the diabetes drug INVOKANA. The action was discontinued in April 2025.
    Read more

  • Janssen Inc. v Pharmascience Inc.

    Counsel: Marian Wolanski
    Belmore Neidrauer secured another victory in the Federal Court of Appeal for our client Janssen relating to the validity of Janssen’s patent covering INVEGA SUSTENNA®
    Read more

  • Janssen Inc. v Apotex Inc.

    Counsel: Marian Wolanski
    We successfully represented Janssen on another appeal relating to infringement of Janssen’s patent covering INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product for the treatment of schizophrenia.
    Read more

  • Janssen v. Pharmascience

    Counsel: Marian Wolanski
    We successfully represented Janssen in the Federal Court of Appeal on this appeal relating to infringement of the patent covering Janssen’s INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product for the treatment of schizophrenia.
    Read more

  • Janssen Inc. v Apotex Inc.

    Counsel: Marian Wolanski
    Belmore Neidrauer has successfully represented Janssen on another appeal, resulting in a decision overturning the Federal Court’s denial of summary judgment.
    Read more

  • Janssen Inc. et al v. Teva Canada Limited

    Counsel: Marian Wolanski
    We successfully represented Janssen on Teva’s appeal and Janssen’s cross-appeal in a significant decision relating to the law of inducing patent infringement in Canada. The decision relates to Janssen’s patent covering INVEGA SUSTENNA® (paliperidone ...
    Read more

  • Janssen v. Apotex

    We successfully represented Janssen in a motion to appeal an order of the Associate Judge which declined, based on relevance, to compel Apotex to answer certain discovery questions related to its ability to supply its generic abiraterone acetate prod...
    Read more

  • Janssen v. Apotex

    We successfully represented Janssen in a motion to Amend its Statement of Defence in this PMNOC section 8 damages action. The Court agreed that Janssen was allowed to amend its Statement of Defence to raise issues as to Apotex’s ability to supply the...
    Read more

  • Janssen v. Dr. Reddy

    We successfully represented Janssen in this motion brought by Dr. Reddy’s in the context of a PMNOC section 8 damages action. Dr. Reddy’s was seeking to have a question of law determined before trial. The question of law related to whether Janssen co...
    Read more

  • Janssen v. Pharmascience

    Counsel: Marian Wolanski
    We successfully represented Janssen in a motion brought by the appellant (Pharmascience) to settle the contents of the appeal book in the context of an appeal from the judgment of the Federal Court in Janssen Inc. v. Pharmascience Inc., 2022 FC 1218 ...
    Read more

  • Alexion v. Attorney General of Canada

    Counsel: Marian Wolanski
    This was an application to add an inventor to two patents owned by Alexion Pharmaceuticals. The patents relate to Alexion’s blockbuster drug SOLIRIS. The application was granted, ensuring that the correct inventors are named on the patents relating t...
    Read more

  • Apotex Inc. v Janssen Inc. et al

    We successfully represented Janssen on these motions seeking non-party discovery in three PMNOC section 8 actions.Each of Apotex, Dr. Reddy’s and Pharmascience resisted, on numerous grounds, non-party discovery for use in these section 8 actions. The...
    Read more

  • Janssen v. Pharmascience

    Counsel: Marian Wolanski
    We successfully represented Janssen in defending the validity of the patent relating to Janssen’s INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product used to treat schizophrenia.
    Read more

  • Janssen v Apotex

    Counsel: Marian Wolanski
    We successfully represented Janssen in this summary trial in the Federal Court on infringement issues against Apotex in respect of Janssen’s patent covering its important INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product used t...
    Read more

  • Janssen v Pharmascience

    Counsel: Marian Wolanski
    We successfully represented Janssen in this summary trial in the Federal Court on infringement issues against Pharmascience in respect of Janssen’s patent covering its important INVEGA SUSTENNA® (paliperidone palmitate) once-monthly injection product...
    Read more
See all cases

Awards

Consistently Recognized
for Excellence.

We are consistently recognized as leading IP litigators in Canada. Among others, we are recognized by:

LEXPERT® CANADIAN LEXPERT DIRECTORY 2023 - MOST FREQUENTLY RECOMMENDED FOR INTELLECTUAL PROPERTY LITIGATION

Mar 1, 2023, 14:31 PM
Ranking / Award Title : LEXPERT® CANADIAN LEXPERT DIRECTORY 2023 - MOST FREQUENTLY RECOMMENDED FOR INTELLECTUAL PROPERTY LITIGATION
Years Awarded : 2023
Accolade Name / Recognition : MOST FREQUENTLY RECOMMENDED FOR INTELLECTUAL PROPERTY LITIGATION
Award Summary : MOST FREQUENTLY RECOMMENDED FOR INTELLECTUAL PROPERTY LITIGATION
Featured : Yes
Last Awarded : Jul 5, 2023, 00:00 AM
Sort Date : Jul 5, 2023, 00:00 AM
Award types :
  • Firm Award
Award publishers : Lexpert®
Related Team Member
Related Expertise
Related Sectors